Prescripción apropiada, adherencia y seguridad de los antiinflamatorios no esteroideos

Brune, 2015, New insights into the use of currently available non-steroidal anti-inflammatory drugs, J Pain Res., 8, 105, 10.2147/JPR.S75160

Laine, 2002, Sratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis, Gastroenterology, 123, 1006, 10.1053/gast.2002.36013

U. S. Food and Drug Administration. FDA news release, April 2005. FDA announces series of changes to the class of marketed non-steroidal anti-inflammatory drugs (NSAIDs) [consultado Jul 2010]. Disponible en: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108427.htm

Lanas, 2014, Safe prescription recommendations for non steroidal anti-inflammatory drugs: Consensus document ellaborated by nominated experts of three scientific associations (SER-SEC-AEG), Gastroenterol Hepatol., 37, 107, 10.1016/j.gastrohep.2013.11.014

Hochberg, 2012, American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee, Arthritis Care Res (Hoboken)., 64, 465, 10.1002/acr.21596

Bjordal, 2004, Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: Meta-analysis of randomised placebo controlled trials, BMJ., 329, 1317, 10.1136/bmj.38273.626655.63

Moore, 2005, Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: Systematic review and meta-analysis of information from company clinical trial reports, Arthritis Res Ther, 7, R644, 10.1186/ar1704

Hernández-Díaz, 2000, Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. An overview of epidemiologic studies published in the 1990s, Arch Intern Med, 160, 2093, 10.1001/archinte.160.14.2093

Lanas, 2009, Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice, Am J Gastroenterol., 104, 1633, 10.1038/ajg.2009.164

Conroy, 2003, Estimation of ten-year risk of mortal cardiovascular disease in Europe: The SCORE project, Eur Heart J., 24, 987, 10.1016/S0195-668X(03)00114-3

McGettigan, 2011, Cardiovascular risk with non-steroidal anti-inflammatory drugs: Systematic review of population-based controlled observational studies, PLoS Med., 8, e1001098, 10.1371/journal.pmed.1001098

European Medicines Agency. Questions and answers on the review of non-selective non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk. London: EMA; 2012 [actualizado 3 May 2013; consultado 22 Jul 2013]. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2012/10/WC500134095.pdf

Bhala, 2013, Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials, Lancet., 382, 769, 10.1016/S0140-6736(13)60900-9

Agencia Española de Medicamentos y Productos Sanitarios. Riesgo cardiovascular de dosis altas de ibuprofeno o dexibuprofeno: recomendaciones de uso [consultado 1 Jun 2015]. Disponible en: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2015/NI-MUH_FV_04-ibuprofeno-dexibuprofeno.htm

Chan, 2010, Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): A randomised trial, Lancet., 376, 173, 10.1016/S0140-6736(10)60673-3

Moore, 2013, Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: Meta-analysis of 51,000 patients enrolled in 52 randomized trials, Arthritis Res Ther., 15, R6, 10.1186/ar4134

Gladding, 2008, The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers, Am J Cardiol., 101, 1060, 10.1016/j.amjcard.2007.11.054

Schjerning Olsen, 2011, Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: A nationwide cohort study, Circulation., 123, 2226, 10.1161/CIRCULATIONAHA.110.004671

Lanas, 2010, Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: The LOGICA study, Ann Rheum Dis., 69, 1453, 10.1136/ard.2009.123166

Lanas, 2011, Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis, BMC Med., 9, 38, 10.1186/1741-7015-9-38

Lanas, 2015, Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: The EVIDENCE study of European routine practice, Ann Rheum Dis., 74, 675, 10.1136/annrheumdis-2013-204155

Van Soest, 2011, Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: An observational study using three European databases, Gut., 60, 1650, 10.1136/gut.2011.239848

Lanas, 2012, Prescription of and adherence to non-steroidal anti-inflammatory drugs and gastroprotective agents in at-risk gastrointestinal patients, Am J Gastroenterol., 107, 707, 10.1038/ajg.2012.13

Laine, 2009, Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines, Aliment Pharmacol Ther., 30, 767, 10.1111/j.1365-2036.2009.04090.x

Lanas, 2009, Education-based approach to addressing non-evidence-based practice in preventing NSAID-associated gastrointestinal complications, World J Gastroenterol., 15, 5953, 10.3748/wjg.15.5953

Helsper, 2009, Trends and determinants of adequate gastroprotection in patients chronically using NSAIDs, Pharmacoepidemiol Drug Saf., 18, 800, 10.1002/pds.1783

Goldstein, 2006, Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications, Clin Gastroenterol Hepatol., 4, 1337, 10.1016/j.cgh.2006.08.016

Capel, 2014, Efficiency of naproxen/esomeprazole in association for osteoarthrosis treatment in Spain, Reumatol Clin., 10, 210, 10.1016/j.reuma.2013.11.009

Bello, 2015, One-year safety of ibuprofen/famotidine fixed combination versus ibuprofen alone: Pooled analyses of two 24-week randomized, double-blind trials and a follow-on extension, Curr Med Res Opin., 31, 407, 10.1185/03007995.2014.1000086

Castellano, 2014, A polypill strategy to improve adherence: Results from the FOCUS project, J Am Coll Cardiol., 64, 2071, 10.1016/j.jacc.2014.08.021